Hospital
Bon Secours ST. Mary's Hospital of Richmond LLC
Bon Secours ST. Mary's Hospital of Richmond LLC was paid $83.03M by Medicaid between Jan 2018 and Dec 2024, across 495 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoBON SECOURS ST. MARY'S HOSPITAL OF RICHMOND LLC
RICHMOND, VA 23226
RICHMOND, VA 23226
33aNPI1962464016assigned 04/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$83.03M
24GClaims2,107,366
24DCodes billed495
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#4 of 80
Median peer was paid$14.69M
This provider vs. median5.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 195,073 | $6.42M | |
| 2019 | 241,954 | $8.33M | |
| 2020 | 218,128 | $8.22M | |
| 2021 | 342,581 | $11.65M | |
| 2022 | 361,538 | $14.43M | |
| 2023 | 401,586 | $17.29M | |
| 2024incomplete | 346,506 | $16.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 83,754 | 73,653 | $14.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 56,498 | 48,915 | $9.54M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.9% | 28,302 | 24,259 | $4.92M |
| 41899 | Unlisted procedure, dentoalveolar structures | 5.5% | 3,775 | 3,294 | $4.59M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.1% | 15,681 | 11,931 | $4.21M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.0% | 6,897 | 5,929 | $3.32M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.3% | 31,924 | 23,580 | $2.71M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 10,406 | 9,155 | $2.43M |
| G0378 | Hospital observation service, per hour | 2.5% | 14,062 | 8,586 | $2.09M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 11,872 | 10,308 | $2.02M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 12,887 | 11,451 | $1.95M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.8% | 2,884 | 2,499 | $1.47M |
483 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 4,532 | $1.26M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.3% | 1,620 | $1.11M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.2% | 1,710 | $1.03M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 22,551 | $1.00M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.2% | 3,054 | $986K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.1% | 1,467 | $888K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,364 | $784K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,077 | $777K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,588 | $694K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,932 | $639K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,192 | $632K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 827 | $604K |
| 95811 | <1% | 1,135 | $580K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 3,724 | $554K |
| 80053 | Comprehensive metabolic panel | <1% | 102,047 | $524K |
| 97161 | <1% | 6,101 | $505K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,245 | $473K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 427 | $452K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,573 | $428K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,643 | $416K |
| 95806 | <1% | 750 | $401K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,930 | $394K |
| 95819 | <1% | 1,598 | $392K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,820 | $382K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,926 | $367K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12,448 | $338K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,902 | $321K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,488 | $308K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 531 | $283K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,910 | $279K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 26,122 | $279K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,780 | $274K |
| 70496 | <1% | 1,066 | $270K | |
| 93971 | <1% | 2,663 | $243K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 25,889 | $240K |
| 76642 | <1% | 2,313 | $238K | |
| 80061 | Lipid panel | <1% | 38,669 | $235K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,985 | $229K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 2,273 | $225K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13,995 | $222K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,099 | $220K |
| 43235 | <1% | 374 | $216K | |
| 94010 | <1% | 3,574 | $206K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,955 | $200K |
| 72141 | <1% | 1,134 | $192K | |
| 76536 | <1% | 1,692 | $191K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13,102 | $187K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 35,432 | $186K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 89,987 | $168K |
| 74018 | <1% | 7,641 | $148K | |
| J2704 | Injection, propofol, 10 mg | <1% | 32,013 | $148K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,512 | $148K |
| 76830 | Ultrasound, transvaginal | <1% | 2,308 | $147K |
| 76770 | <1% | 1,198 | $135K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 136,358 | $128K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,894 | $124K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 21,719 | $117K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 9,841 | $116K |
| 86803 | <1% | 11,279 | $114K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,371 | $114K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 3,721 | $113K |
| 70491 | <1% | 548 | $112K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 788 | $111K |
| 93798 | <1% | 1,086 | $111K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 96 | $109K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 36,493 | $107K |
| 95816 | <1% | 531 | $106K | |
| 93970 | <1% | 892 | $106K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 61 | $106K |
| 74183 | <1% | 321 | $104K | |
| 85027 | <1% | 25,995 | $104K | |
| 97116 | <1% | 3,698 | $98K | |
| 97162 | <1% | 669 | $97K | |
| 71250 | <1% | 1,500 | $96K | |
| 12011 | <1% | 430 | $88K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,041 | $84K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,689 | $84K |
| 77072 | <1% | 1,486 | $83K | |
| 80050 | General health panel | <1% | 7,808 | $83K |
| 84439 | <1% | 9,827 | $81K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,232 | $80K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 989 | $78K |
| 12001 | <1% | 393 | $77K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,132 | $76K |
| 97014 | <1% | 2,561 | $73K | |
| 70498 | <1% | 1,231 | $71K | |
| 77080 | <1% | 1,148 | $71K | |
| 97165 | <1% | 1,637 | $69K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 477 | $68K |
| 72100 | <1% | 3,800 | $66K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,530 | $63K |
| 83880 | <1% | 5,532 | $62K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 562 | $62K |
| 76801 | <1% | 1,960 | $61K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13,115 | $60K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 421 | $58K |
| 95800 | <1% | 357 | $56K | |
| 82607 | <1% | 5,750 | $53K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,330 | $52K |
| 97016 | <1% | 2,013 | $51K | |
| 82728 | <1% | 5,638 | $51K | |
| 74240 | <1% | 487 | $50K | |
| 95714 | <1% | 146 | $50K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 326 | $49K |
| 97803 | <1% | 549 | $49K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,640 | $48K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,026 | $47K |
| 58571 | <1% | 20 | $47K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,330 | $46K |
| 93017 | <1% | 773 | $45K | |
| 47562 | <1% | 17 | $44K | |
| 73562 | <1% | 4,182 | $43K | |
| 73221 | <1% | 216 | $41K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,259 | $41K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 10,745 | $40K |
| 99218 | <1% | 3,587 | $40K | |
| 87040 | <1% | 5,788 | $40K | |
| 70486 | <1% | 658 | $39K | |
| 81001 | <1% | 46,201 | $35K | |
| 76870 | <1% | 363 | $33K | |
| 71271 | <1% | 335 | $32K | |
| 83550 | <1% | 5,917 | $32K | |
| 94060 | <1% | 428 | $31K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 728 | $31K |
| 82570 | <1% | 7,725 | $31K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 915 | $30K |
| 73030 | <1% | 2,509 | $30K | |
| 73130 | <1% | 2,140 | $28K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 35,904 | $28K |
| 86780 | <1% | 2,854 | $28K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 353 | $28K |
| 84484 | <1% | 23,284 | $27K | |
| 82962 | <1% | 24,385 | $26K | |
| 95812 | <1% | 43 | $26K | |
| 73630 | <1% | 2,827 | $26K | |
| 72050 | <1% | 1,066 | $25K | |
| 87340 | <1% | 4,447 | $25K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 39,476 | $25K |
| 99385 | <1% | 176 | $24K | |
| 83540 | <1% | 6,150 | $24K | |
| 85379 | <1% | 5,181 | $23K | |
| 93308 | <1% | 92 | $23K | |
| 72131 | <1% | 320 | $22K | |
| 84153 | <1% | 2,024 | $22K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,393 | $20K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 155 | $20K |
| 86850 | <1% | 6,571 | $20K | |
| 74241 | <1% | 186 | $20K | |
| 82043 | <1% | 7,211 | $20K | |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 47 | $19K |
| 88307 | <1% | 1,571 | $19K | |
| 86592 | <1% | 3,652 | $19K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,494 | $18K |
| 82746 | <1% | 2,878 | $17K | |
| 87522 | Neg quan hep c or qual rna | <1% | 718 | $16K |
| J3490 | Unclassified drugs | <1% | 26,212 | $16K |
| 73502 | <1% | 1,529 | $16K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 29,060 | $16K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,539 | $16K |
| 80076 | <1% | 3,036 | $15K | |
| S9472 | Cardiac rehabilitation program, non-physician provider, per diem | <1% | 151 | $15K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,361 | $15K |
| 84403 | <1% | 1,135 | $15K | |
| 73610 | <1% | 2,609 | $15K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,828 | $14K |
| 0042T | <1% | 73 | $14K | |
| 84702 | <1% | 4,154 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 27,101 | $14K |
| 90715 | <1% | 824 | $13K | |
| 87070 | <1% | 11,847 | $13K | |
| 76882 | <1% | 143 | $13K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 560 | $12K |
| 83735 | <1% | 13,614 | $12K | |
| 85610 | <1% | 8,680 | $12K | |
| 93458 | <1% | 16 | $12K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 543 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 431 | $12K |
| 10060 | <1% | 140 | $11K | |
| 81025 | <1% | 24,268 | $11K | |
| 86900 | <1% | 6,846 | $11K | |
| 86038 | <1% | 1,418 | $11K | |
| 76820 | <1% | 277 | $11K | |
| 84402 | <1% | 758 | $11K | |
| 86140 | <1% | 5,434 | $11K | |
| 45384 | <1% | 17 | $10K | |
| 86706 | <1% | 1,880 | $10K | |
| 83001 | <1% | 819 | $10K | |
| 70360 | <1% | 452 | $10K | |
| 87077 | <1% | 6,067 | $10K | |
| 84145 | <1% | 1,348 | $10K | |
| 80074 | <1% | 631 | $10K | |
| 76818 | <1% | 112 | $10K | |
| 82784 | <1% | 1,356 | $9K | |
| 90674 | <1% | 373 | $9K | |
| 88304 | <1% | 2,058 | $9K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 253 | $9K |
| 90714 | <1% | 419 | $9K | |
| 76885 | <1% | 78 | $9K | |
| 87186 | <1% | 5,663 | $9K | |
| 74019 | <1% | 2,629 | $9K | |
| 86762 | <1% | 1,586 | $9K | |
| 86376 | <1% | 676 | $9K | |
| 84146 | <1% | 673 | $8K | |
| 86704 | <1% | 1,150 | $8K | |
| 76937 | <1% | 581 | $8K | |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 89 | $8K |
| 85652 | <1% | 5,304 | $8K | |
| 82107 | <1% | 340 | $8K | |
| 90661 | <1% | 275 | $8K | |
| 83690 | <1% | 18,655 | $8K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 4,666 | $8K |
| 83020 | <1% | 1,072 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 18,352 | $8K |
| 83002 | <1% | 739 | $7K | |
| 87081 | <1% | 1,176 | $7K | |
| 86901 | <1% | 6,842 | $7K | |
| 86787 | <1% | 1,458 | $7K | |
| 83605 | <1% | 4,660 | $7K | |
| 72197 | <1% | 27 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,629 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 948 | $6K |
| 83721 | <1% | 967 | $6K | |
| 87150 | <1% | 255 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,936 | $6K |
| 82950 | <1% | 1,640 | $6K | |
| 83520 | <1% | 591 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,049 | $6K |
| 73110 | <1% | 892 | $6K | |
| 74230 | <1% | 72 | $6K | |
| 83516 | <1% | 529 | $6K | |
| 82550 | <1% | 3,983 | $6K | |
| 86480 | <1% | 477 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 20,431 | $6K |
| 80179 | <1% | 1,930 | $6K | |
| 72072 | <1% | 402 | $6K | |
| 70310 | <1% | 2,697 | $6K | |
| 70544 | <1% | 15 | $5K | |
| 80143 | <1% | 1,953 | $5K | |
| 84703 | <1% | 3,153 | $5K | |
| 64415 | <1% | 26 | $5K | |
| 88342 | <1% | 2,406 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15,237 | $5K |
| 73590 | <1% | 774 | $5K | |
| 87506 | <1% | 148 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 20,932 | $5K |
| G0008 | Administration of influenza virus vaccine | <1% | 1,168 | $5K |
| 80047 | <1% | 1,079 | $5K | |
| 99152 | <1% | 2,082 | $5K | |
| 85018 | <1% | 2,908 | $5K | |
| 84480 | <1% | 590 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,071 | $5K |
| 87147 | <1% | 2,955 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 22,319 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,726 | $4K |
| 84550 | <1% | 1,637 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 21,616 | $4K |
| 86200 | <1% | 513 | $4K | |
| 81003 | <1% | 3,270 | $4K | |
| 86235 | <1% | 107 | $4K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,250 | $4K |
| 77061 | <1% | 162 | $4K | |
| 73140 | <1% | 776 | $4K | |
| 84436 | <1% | 535 | $3K | |
| 85730 | <1% | 3,225 | $3K | |
| 77062 | <1% | 175 | $3K | |
| 86696 | <1% | 382 | $3K | |
| 86431 | <1% | 670 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,967 | $3K |
| 96367 | <1% | 156 | $3K | |
| 82172 | <1% | 313 | $3K | |
| 90686 | <1% | 383 | $3K | |
| 86141 | <1% | 365 | $3K | |
| 96376 | <1% | 8,685 | $3K | |
| 92611 | <1% | 58 | $3K | |
| 86800 | <1% | 314 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,458 | $2K |
| 95886 | <1% | 29 | $2K | |
| 83970 | <1% | 91 | $2K | |
| 97802 | <1% | 130 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,937 | $2K |
| C1776 | Joint device (implantable) | <1% | 113 | $2K |
| 83021 | <1% | 124 | $2K | |
| 86695 | <1% | 286 | $2K | |
| 82670 | <1% | 168 | $2K | |
| 88341 | <1% | 319 | $2K | |
| 82553 | <1% | 476 | $2K | |
| 84100 | <1% | 3,178 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 626 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 9,057 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,079 | $2K |
| 87521 | Neg quan hep c or qual rna | <1% | 89 | $2K |
| 82803 | <1% | 1,981 | $2K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 28 | $2K |
| 82247 | <1% | 498 | $2K | |
| 73080 | <1% | 479 | $2K | |
| 82077 | <1% | 3,354 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,853 | $2K |
| 72040 | <1% | 167 | $2K | |
| 86003 | <1% | 78 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 51 | $2K |
| 0100U | <1% | 80 | $2K | |
| 84156 | <1% | 905 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 72 | $2K |
| 86364 | <1% | 502 | $2K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 79 | $2K |
| 80069 | <1% | 320 | $2K | |
| 82465 | <1% | 345 | $1K | |
| 90694 | <1% | 130 | $1K | |
| 87210 | <1% | 3,605 | $1K | |
| 80164 | <1% | 240 | $1K | |
| 87205 | <1% | 1,934 | $1K | |
| 87634 | <1% | 711 | $1K | |
| 82951 | <1% | 121 | $1K | |
| 93291 | <1% | 48 | $1K | |
| 73700 | <1% | 13 | $1K | |
| 83615 | <1% | 596 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 297 | $1K |
| 84425 | <1% | 172 | $1K | |
| 81002 | <1% | 536 | $1K | |
| 95012 | <1% | 30 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,541 | $1K |
| 85014 | <1% | 648 | $1K | |
| 84165 | <1% | 166 | $1K | |
| 80177 | <1% | 208 | $983.94 | |
| 76942 | <1% | 22 | $965.11 | |
| 87088 | <1% | 397 | $951.98 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 29 | $886.24 |
| 83655 | <1% | 76 | $874.25 | |
| 94762 | <1% | 327 | $856.26 | |
| 73560 | <1% | 48 | $835.11 | |
| C1769 | Guide wire | <1% | 2,451 | $823.10 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,290 | $808.31 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 17 | $796.50 |
| 51798 | <1% | 53 | $788.11 | |
| 93225 | <1% | 17 | $784.22 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,238 | $745.38 |
| 10061 | <1% | 16 | $742.95 | |
| 93296 | <1% | 181 | $741.46 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 599 | $713.49 |
| 82150 | <1% | 136 | $693.72 | |
| 87807 | <1% | 2,396 | $680.93 | |
| 0099U | <1% | 54 | $677.83 | |
| 86334 | <1% | 67 | $662.06 | |
| 90653 | <1% | 147 | $661.59 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 5,310 | $650.26 |
| 86225 | <1% | 108 | $633.72 | |
| 36416 | <1% | 688 | $627.83 | |
| 36600 | <1% | 96 | $562.40 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,292 | $542.04 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,452 | $524.59 |
| 73090 | <1% | 320 | $512.20 | |
| 84132 | <1% | 744 | $502.11 | |
| 82627 | <1% | 29 | $502.06 | |
| 82105 | <1% | 32 | $483.58 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,164 | $483.34 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 3,528 | $481.55 |
| 86708 | <1% | 87 | $463.97 | |
| 85660 | <1% | 134 | $436.75 | |
| 82140 | <1% | 109 | $420.42 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,674 | $383.47 |
| 82330 | <1% | 437 | $379.46 | |
| 97760 | <1% | 15 | $378.16 | |
| 82952 | <1% | 121 | $363.48 | |
| 82565 | <1% | 255 | $330.17 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,315 | $303.78 |
| 83498 | <1% | 15 | $297.16 | |
| 86231 | <1% | 102 | $282.48 | |
| 86258 | <1% | 78 | $281.65 | |
| 85045 | <1% | 170 | $275.91 | |
| 83695 | <1% | 28 | $275.00 | |
| 82977 | <1% | 56 | $258.46 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,414 | $233.17 |
| 87486 | <1% | 17 | $230.52 | |
| 82248 | <1% | 140 | $227.02 | |
| 84481 | <1% | 42 | $219.80 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 78 | $218.88 |
| 84681 | <1% | 17 | $217.76 | |
| 85007 | <1% | 953 | $212.33 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 3,098 | $211.73 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,592 | $193.20 |
| 93797 | <1% | 58 | $167.88 | |
| 82947 | <1% | 338 | $164.61 | |
| 82785 | <1% | 12 | $163.63 | |
| 86015 | <1% | 29 | $159.18 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 16 | $156.24 |
| 86677 | <1% | 13 | $153.00 | |
| 86308 | <1% | 216 | $135.75 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 833 | $134.87 |
| 83521 | <1% | 12 | $124.63 | |
| 73620 | <1% | 17 | $123.51 | |
| 86665 | <1% | 15 | $118.99 | |
| 82272 | <1% | 628 | $118.69 | |
| 86735 | <1% | 19 | $118.54 | |
| 87581 | <1% | 17 | $115.31 | |
| 99497 | <1% | 46 | $113.28 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 1,515 | $113.08 |
| 51701 | <1% | 475 | $111.41 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 185 | $109.98 |
| 83718 | <1% | 12 | $90.47 | |
| 82390 | <1% | 14 | $78.66 | |
| 86765 | <1% | 19 | $78.54 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 781 | $73.83 |
| 71101 | <1% | 13 | $72.27 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 409 | $66.32 |
| 74022 | <1% | 53 | $64.25 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 727 | $60.48 |
| 73660 | <1% | 29 | $59.59 | |
| 73552 | <1% | 32 | $48.17 | |
| 88271 | <1% | 15 | $44.12 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 281 | $41.06 |
| 86664 | <1% | 15 | $40.21 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,693 | $36.10 |
| 94664 | <1% | 362 | $33.67 | |
| 84295 | <1% | 234 | $30.45 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 692 | $30.29 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 13 | $28.55 |
| 87045 | <1% | 27 | $26.88 | |
| 87427 | <1% | 28 | $26.83 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 719 | $26.52 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 87 | $21.18 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 346 | $19.93 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,357 | $15.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 1,628 | $15.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 799 | $14.70 |
| 87899 | <1% | 28 | $13.44 | |
| 87046 | <1% | 27 | $13.44 | |
| 94760 | <1% | 1,964 | $12.50 | |
| 82657 | <1% | 480 | $12.08 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,617 | $7.90 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 54 | $7.32 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 35 | $4.36 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 81 | $4.32 |
| A4565 | Slings | <1% | 245 | $3.83 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 146 | $3.65 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 51 | $3.45 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 14 | $2.34 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 15 | $2.34 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 15 | $1.64 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 57 | $1.34 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 42 | $0.54 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,877 | $0.04 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 333 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 310 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 333 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 13 | $0.00 |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 33 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 436 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 397 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 1,054 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 117 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 126 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 164 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 23 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 58 | $0.00 |
| 69210 | 0% | 12 | $0.00 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 76 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 13 | $0.00 |
| 76000 | 0% | 14 | $0.00 | |
| 96138 | 0% | 12 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 14 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 593 | $0.00 |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | 0% | 70 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 234 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 310 | $0.00 |
| A9270 | Non-covered item or service | 0% | 3,968 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 1,413 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 339 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 123 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 199 | $0.00 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 112 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 35 | $0.00 |
| 88300 | 0% | 87 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 15 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 198 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 18 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 31 | $0.00 |
| 94761 | 0% | 110 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 77 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 175 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 21 | $0.00 |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | 0% | 16 | $0.00 |
| 70300 | 0% | 27 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.